Benjamin Wolin - Rockwell Medical Chairman of the Board
| RMTI Stock | USD 1.45 0.03 2.03% |
Chairman
Mr. Benjamin Wolin is Independent Chairman of the Board of the Rockwell Medical, Inc. Mr. Wolin serves on the Board of Dance Biopharm Holdings Inc., a privatelyheld biotechnology company focused on the development of Dance 501, a proprietary oftmist inhaled insulin product to treat diabetes. He is also as an advisor to each of 3L Capital LLC, a growthstage private equity firm, and Refinery 29 Inc., a leading global media company. Prior to his experience as an advisor, Mr. Wolin was the cofounder, chief executive officer and a member of the board of directors of Everyday Health, Inc., a leading provider of digital health and wellness solutions, from January 2002 until its sale to a subsidiary of j2 Global, Inc. in December 2016. From September 1999 until December 2001, Mr. Wolin served as vice president of production and technology for Beliefnet, Inc., an online provider of religious and spiritual information. Previously, Mr. Wolin served as web producer for Tribune Interactive, Inc., a multimedia corporation, and held several consulting positions with interactive companies. Mr. Wolin is also Lead Independent Director of Diplomat Pharmacy, Inc., the largest independent provider of specialty pharmacy services in the United States. Mr. Wolin was a director of Diplomat Pharmacy since October 2015 and was formerly Diplomat Pharmacy Chairman of the Board. Mr. Wolin is a member of the audit committee, compensation committee and the nominating and corporate governance committee of Diplomat Pharmacy board of directors. Mr. Wolin has extensive technology, executive management, entrepreneurial, financial and operating expertise from his former role as a founder, director and principal executive of Everyday Health. since 2018.
| Age | 43 |
| Tenure | 6 years |
| Address | 30142 South Wixom road, Wixom, MI, United States, 48393 |
| Phone | 248 960 9009 |
| Web | https://www.rockwellmed.com |
Rockwell Medical Management Efficiency
The company has return on total asset (ROA) of (0.0844) % which means that it has lost $0.0844 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4768) %, meaning that it created substantial loss on money invested by shareholders. Rockwell Medical's management efficiency ratios could be used to measure how well Rockwell Medical manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.22. The current Return On Capital Employed is estimated to decrease to -0.2. As of now, Rockwell Medical's Total Current Assets are increasing as compared to previous years. The Rockwell Medical's current Intangible Assets is estimated to increase to about 13 M, while Total Assets are projected to decrease to under 37.3 M.Similar Executives
| Found 9 records | CHAIRMAN Age | ||
| G Prasad | Dr Reddys Laboratories | 59 | |
| David Stack | Pacira Pharmaceuticals | 74 | |
| Craig Stapleton | Avadel Pharmaceuticals PLC | 70 | |
| Bryan Roberts | Ironwood Pharmaceuticals | 47 | |
| Michael Heffernan | Collegium Pharmaceutical | 53 | |
| Richard Pops | Alkermes Plc | 62 | |
| Satish Reddy | Dr Reddys Laboratories | 52 | |
| Robert Brown | ANI Pharmaceuticals | 67 | |
| William Rastetter | Neurocrine Biosciences | 69 | |
Management Performance
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.0844 |
Rockwell Medical Leadership Team
Elected by the shareholders, the Rockwell Medical's board of directors comprises two types of representatives: Rockwell Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rockwell. The board's role is to monitor Rockwell Medical's management team and ensure that shareholders' interests are well served. Rockwell Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rockwell Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Cooper, Director | ||
| David Domzalski, Director | ||
| Angus Smith, Principal Financial Officer | ||
| Thomas Klema, CFO, Vice President Treasurer, Secretary | ||
| Mark Strobeck, CEO President | ||
| Marc MD, Chief Officer | ||
| James McCarthy, Senior Development | ||
| Timothy Chole, Senior Marketing | ||
| Mark Ravich, Director | ||
| Michael DeYoung, Vice President - Operations | ||
| Kenneth Holt, Independent Director | ||
| Benjamin Wolin, Chairman of the Board | ||
| Paul McGarry, Principal Accounting Officer, Vice President Corporate Controller | ||
| Megan Timmins, Chief VP | ||
| Patrick Bagley, Independent Director | ||
| David Kull, Principal Accounting Officer | ||
| Jim McCarthy, Senior Vice President - Corporate and Business Development | ||
| Jason Finkelstein, Investor Representative | ||
| Ajay Gupta, Chief Scientific Officer | ||
| Ronald Boyd, Independent Director | ||
| Lisa Colleran, Director | ||
| Jesse Neri, Senior Finance | ||
| Charlie Shiner, Vice President of Marketing | ||
| Raymond Pratt, Chief Medical Officer | ||
| Robin Smith, Director | ||
| Robert Chioini, Founder, Chairman of The Board and CEO | ||
| Heather Hunter, Senior Officer | ||
| Michael Rice, Co-Founder, LifeSci Advisors, LLC | ||
| Stuart Paul, CEO, Director |
Rockwell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rockwell Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.0844 | ||||
| Profit Margin | (0.10) % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 46.21 M | ||||
| Shares Outstanding | 29.36 M | ||||
| Shares Owned By Insiders | 3.00 % | ||||
| Shares Owned By Institutions | 17.40 % | ||||
| Number Of Shares Shorted | 675.7 K | ||||
| Price To Earning | (14.72) X |
Currently Active Assets on Macroaxis
When determining whether Rockwell Medical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rockwell Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rockwell Medical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rockwell Medical Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rockwell Medical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Rockwell Stock please use our How to Invest in Rockwell Medical guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for Rockwell Stock analysis
When running Rockwell Medical's price analysis, check to measure Rockwell Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rockwell Medical is operating at the current time. Most of Rockwell Medical's value examination focuses on studying past and present price action to predict the probability of Rockwell Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rockwell Medical's price. Additionally, you may evaluate how the addition of Rockwell Medical to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Stocks Directory Find actively traded stocks across global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Rockwell Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rockwell Medical. If investors know Rockwell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rockwell Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share 3.585 | Quarterly Revenue Growth 0.144 | Return On Assets (0.08) | Return On Equity (0.48) |
The market value of Rockwell Medical is measured differently than its book value, which is the value of Rockwell that is recorded on the company's balance sheet. Investors also form their own opinion of Rockwell Medical's value that differs from its market value or its book value, called intrinsic value, which is Rockwell Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rockwell Medical's market value can be influenced by many factors that don't directly affect Rockwell Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rockwell Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Rockwell Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rockwell Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.